Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Juan M. Maldonado"'
2
Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial
Autor: Giulia Ferrannini, Juan M. Maldonado, Sohini Raha, Purnima Rao-Melacini, Rutaba Khatun, Charles Atisso, Linda Shurzinske, Hertzel C. Gerstein, Lars Rydén, M. Angelyn Bethel
Publikováno v: Scandinavian Cardiovascular Journal. 57
Objectives. To assess whether the use of cardioprotective therapies for type 2 diabetes varies by gender and whether the risk of cardiovascular events is higher in women versus men in the REWIND trial, including an international type 2 diabetes patie
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d71bb0551b59f6718d31a47c413065a4
https://doi.org/10.1080/14017431.2023.2166101
Zobrazit plný text záznamu
3
Roux-en-Y gastric bypass in the elderly: is age a determining factor in our outcomes?
Autor: Nicolás Laborda, Agostina Montanelli, Matías J. Turchi, Juan M. Maldonado, Felipe E. Fiolo, Feike Kingma
Publikováno v: Surgery for Obesity and Related Diseases. 16:1514-1520
While patients are becoming older and the prevalence of obesity increases worldwide, literature on the impact of age on outcomes after laparoscopic Roux-en-Y gastric bypass (LRYGB) is scarce. The balance between surgical risks and clinical benefits o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ffd8842975c7a8c14814976c9c9417
https://doi.org/10.1016/j.soard.2020.05.015
Zobrazit plný text záznamu
4
Cardiovascular outcomes trials with glucagon‐like peptide‐1 receptor agonists: A comparison of study designs, populations and results
Autor: Kevin M. Pantalone, Juan M. Maldonado, Oralee J. Varnado, Clinton M. Hasenour, Kashif M. Munir, Charles Atisso, Manige Konig
Publikováno v: Diabetes, Obesity & Metabolism
Despite treatment advances leading to improved outcomes over the past 2 decades, cardiovascular (CV) disease (CVD) remains the leading cause of morbidity and mortality in people with diabetes. People with type 2 diabetes (T2D) have a 2‐ to 4‐fold
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7818d1fcf468077bcacd4fa8ecdeb8b2
https://doi.org/10.1111/dom.14165
Zobrazit plný text záznamu
5
LBSUN319 Characteristics And Treatment Patterns Of Hispanic/latino Patients Initiating First Injectable Glp-1ra Or Basal Insulin
Autor: Meredith Hoog, Juan M Maldonado, Rachel Halpern, Indu Dhangar, Erin Buysman, Kim McNiff, Manige Konig
Publikováno v: Journal of the Endocrine Society. 6:A294-A294
Hispanic/Latino (H/L) adults in the United States have greater prevalence of T2D and diabetes-related complications compared to non-Hispanic/Latinos (nH/L). Optimal glycemic control remains a challenge in H/L patients, resulting in poor health outcom
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b46cc0cb75027190a45189a0555d2f00
https://doi.org/10.1210/jendso/bvac150.607
Zobrazit plný text záznamu
6
673-P: Effect of Once-Weekly Dulaglutide 3.0 and 4.5 mg in Patients with Different Baseline Renal Function: Post-hoc Analysis from the Award-11 Trial
Autor: Kari T. Ranta, Juan M. Maldonado, Sohini Raha, Luis-Emilio Garcia-Perez
Publikováno v: Diabetes. 70
Background: AWARD-11 study in patients with type 2 diabetes on metformin demonstrated similar safety and superior efficacy of dulaglutide (DU) 3.0 and 4.5 mg vs. DU 1.5 mg. A post hoc analysis assessed consistency in safety and efficacy of the three
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85dd05d3bcc62482fddc4d95390ae478
https://doi.org/10.2337/db21-673-p
Zobrazit plný text záznamu
7
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
Autor: Anita Y.M. Kwan, Hertzel C. Gerstein, Jan Basile, Denis Xavier, Juan M. Maldonado, Sohini Raha, Manige Konig
Publikováno v: Diabetes care. 45(3)
OBJECTIVE To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA1c) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42ef5a39ad343abcd2340c25c512e0fb
https://pubmed.ncbi.nlm.nih.gov/35043140
Zobrazit plný text záznamu
9
DULAGLUTIDE REDUCES HBA1C IRRESPECTIVE OF ANTIHYPERGLYCEMIC AGENTS, DURATION OF DIABETES, BMI AND WEIGHT LOSS: A POST HOC ANALYSIS FROM THE REWIND TRIAL
Autor: Hertzel C. Gerstein, Manige Konig, Anita Kwan, Denis Xavier, Sohini Raha, Jan Basile, Juan M. Maldonado
Publikováno v: Journal of the American College of Cardiology. 75:1951
In the REWIND CV outcomes trial, the addition of dulaglutide 1.5 mg (DU) vs placebo (PL) to standard of care reduced the composite risk of CV death, nonfatal MI and nonfatal stroke in patients with type 2 diabetes and prior CV disease or CV risk fact
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b80be386c606c4d84a6872445238ddff
https://doi.org/10.1016/s0735-1097(20)32578-x
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje